Additionally, the European Society of Cardiology (ESC) has incorporated SGLT2 inhibitors into its heart failure and cardiovascular risk reduction guidelines, further reinforcing their role across both diabetic and non-diabetic populations [39]. The gene discussed is SLC5A2; the disease is heart failure.